Search company, investor...

Ardea Biosciences

ardeabiosciences.com

Stage

Acq - P2P | Acquired

Total Raised

$67.8M

Valuation

$0000 

Revenue

$0000 

About Ardea Biosciences

Ardea Biosciences is focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV).

Headquarters Location

4939 Directors Place

San Diego, California, 92121,

United States

858-652-6500

Missing: Ardea Biosciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Ardea Biosciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Ardea Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ardea Biosciences is included in 1 Expert Collection, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Ardea Biosciences Patents

Ardea Biosciences has filed 74 patents.

The 3 most popular patent topics include:

  • Kidney diseases
  • Rare diseases
  • Amino acid metabolism disorders
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/14/2018

2/16/2021

Rare diseases, Autosomal recessive disorders, Amino acid metabolism disorders, Kidney diseases, Syndromes

Grant

Application Date

11/14/2018

Grant Date

2/16/2021

Title

Related Topics

Rare diseases, Autosomal recessive disorders, Amino acid metabolism disorders, Kidney diseases, Syndromes

Status

Grant

Latest Ardea Biosciences News

Xanthine Oxidase Inhibitor Drug Pipeline Research Report 2022 Featuring Fuji Yakuhin, Sanwa Kagaku Kenkyusho, LG Life Sciences, Ardea Biosciences, & Teijin Pharma - ResearchAndMarkets.com

Feb 9, 2022

"Xanthine Oxidase Inhibitor - Pipeline Insight, 2022" report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Xanthine Oxidase Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Descriptive coverage of pipeline development activities for Xanthine Oxidase Inhibitor Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for Xanthine Oxidase Inhibitor The report assesses the active Xanthine Oxidase Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route. Scope of the Report Provides a snapshot of the therapeutics pipeline activity for Xanthine Oxidase Inhibitor Features the Xanthine Oxidase Inhibitor pipeline across the complete product development cycle including all clinical and non-clinical stage. Offers detailed therapeutic product profiles of Xanthine Oxidase Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration Coverage of dormant and discontinued pipeline projects across Xanthine Oxidase Inhibitor Key Topics Covered:

Ardea Biosciences Frequently Asked Questions (FAQ)

  • Where is Ardea Biosciences's headquarters?

    Ardea Biosciences's headquarters is located at 4939 Directors Place, San Diego.

  • What is Ardea Biosciences's latest funding round?

    Ardea Biosciences's latest funding round is Acq - P2P.

  • How much did Ardea Biosciences raise?

    Ardea Biosciences raised a total of $67.8M.

  • Who are the investors of Ardea Biosciences?

    Investors of Ardea Biosciences include AstraZeneca.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.